How To Prepare for an Unpredictable 2021

 

Just about everyone on the world was thrilled to tear off the final page of the 2020 calendar and get a fresh start in the new year.

But, while there is light at the end of the tunnel as the world continues to grapple with the COVID-19 pandemic, the upcoming year could have just as many twists and turns as the one that preceded it.

That’s why Eric Waldinger, Chief Marketing Officer for SambaSafety, believes planning is critical, with companies doing their best to assert their influence over the variables they’re able to control.

“Being prepared for any unexpected losses or incidents that come up is one that you’re going to be able to control in 2021,” Waldinger said.

SambaSafety’s Driver Monitoring tool is one way to do just that, with Waldinger highlighting eight key benefits to the program, including risk mitigation, reducing workload thanks to not pulling MVRs, automating safety programs and simply encouraging safer driving with monthly violations and accidents going down when people understand they’re being monitored.

“If I was able to tell you there was a product out there that could reduce crashes, keep your employers safer and substantially reduce the risk footprint of your organization while saving you significant dollars … Why would you not use this?” Waldinger said.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More